[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Doval DC, Pande SB, Sharma JB, Rao SA, Prakash N, Vaid AK: Report of a case of pericardial mesothelioma with liver metastases responding well to pemetrexed and platinum-based chemotherapy. J Thorac Oncol; 2007 Aug;2(8):780-1
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of a case of pericardial mesothelioma with liver metastases responding well to pemetrexed and platinum-based chemotherapy.
  • Pericardial mesothelioma remains a disease with a bleak prognosis.
  • We report the case of a patient with metastases to liver and good response to pemetrexed and carboplatin-based combination chemotherapy and consequent prolonged progression-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / pathology. Liver Neoplasms / secondary. Mesothelioma / secondary. Pericardium

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762349.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 0 / Platinum Compounds; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


2. Butz T, Faber L, Langer C, Körfer J, Lindner O, Tannapfel A, Müller KM, Meissner A, Plehn G, Trappe HJ, Horstkotte D, Piper C: Primary malignant pericardial mesothelioma - a rare cause of pericardial effusion and consecutive constrictive pericarditis: a case report. J Med Case Rep; 2009;3:9256

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant pericardial mesothelioma - a rare cause of pericardial effusion and consecutive constrictive pericarditis: a case report.
  • INTRODUCTION: Primary malignant pericardial mesothelioma is a very rare pericardial tumor of unknown etiology.
  • CASE PRESENTATION: A 61-year-old Caucasian woman was admitted to our hospital complaining of exertional dyspnea due to a large pericardial effusion.
  • Intrapericardial fluid volume declined after repeated pericardiocentesis, but the patient progressively developed a hemodynamically relevant pericardial constriction.
  • Pericardiectomy revealed a pericardial mesothelioma.
  • Subsequently, four cycles of chemotherapy (dosage according to recently published trials) were administered.
  • CONCLUSION: Pericardial mesothelioma should be considered and managed appropriately in non-responders to pericardiocentesis, and in patients who develop constrictive pericarditis late in their clinical course.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Cardiol. 1999 Dec;15(12):1367-72 [10620743.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):245-8 [16533802.001]
  • [Cites] Lung Cancer. 2008 May;60(2):291-3 [17936406.001]
  • [Cites] Semin Diagn Pathol. 2008 Feb;25(1):47-53 [18350922.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):764-71 [18594323.001]
  • [Cites] Eur Heart J. 2004 Apr;25(7):587-610 [15120056.001]
  • [Cites] Clin Lung Cancer. 2005 Jul;7(1):40-6 [16098243.001]
  • [Cites] Heart. 2006 Sep;92(9):1289 [16908701.001]
  • [Cites] J Thorac Imaging. 2008 Feb;23(1):35-8 [18347518.001]
  • [Cites] Heart. 2004 Jan;90(1):e4 [14676267.001]
  • (PMID = 19918293.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2767155
  •  go-up   go-down


3. Fujimoto N, Gemba K, Wada S, Ono K, Fujii Y, Ozaki S, Ikeda T, Taguchi K, Kunitomo T, Kishimoto T: Malignant pericardial mesothelioma with response to chemotherapy. J Thorac Oncol; 2009 Nov;4(11):1440-1
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma with response to chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Echocardiography. Fatal Outcome. Female. Humans. Middle Aged. Pericardium. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861909.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, Gianni W, Amoroso S, Procopio A: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer; 2004 Apr 10;109(3):322-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention.
  • Malignant mesothelioma (MM) remains the most lethal pleural, peritoneal and pericardial cancer.
  • Celecoxib, in a dose- and time-dependent manner, induced MM cell apoptosis, which involved decreased Akt phosphorylation, loss of Bcl-2 and Survivin protein expression and caspase-3 activation.
  • These data demonstrate that celecoxib may have antitumor properties in MM and provide a rationale for the therapeutic use of celecoxib in combination with a selective VEGF inhibitor.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Mesothelioma / drug therapy. Protein-Serine-Threonine Kinases. Proto-Oncogene Proteins / antagonists & inhibitors. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Caspase 3. Caspases / metabolism. Celecoxib. Chemoprevention. Cyclooxygenase Inhibitors / pharmacology. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazoles. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 14961568.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


5. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C: [Malignant cardiac tumors]. Bull Cancer; 2004 Nov;91 Suppl 3:136-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from primary pericardial mesothelioma, primary cardiac tumors are high-grade sarcomas with a high metastatic potency that often becomes evident early after surgery.
  • Due to its poor prognosis, treatment of cardiac metastases is restricted to best supportive care.
  • For primary cardiac neoplasms, surgery must be carefully discussed because operative intervention is often followed by rapid widespread metastases that adjuvant chemotherapy cannot avoid in most cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899620.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


6. Reardon KA, Reardon MA, Moskaluk CA, Grosh WW, Read PW: Primary pericardial malignant mesothelioma and response to radiation therapy. Rare Tumors; 2010;2(3):e51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial malignant mesothelioma and response to radiation therapy.
  • We report a case of a primary pericardial malignant mesothelioma.
  • Partial resection of the mass was undertaken revealing malignant mesothelioma, byphasic type.
  • The patient was treated with chemotherapy intermittently over a period of 3 years, but his disease continued to progress.
  • The patient was then treated with definitive radiation therapy to 64 Gy to the primary tumor using a six field 3D conformal technique.
  • The patient remains free of progressive disease 86 months from the time of diagnosis and 50 months from the completion of his radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139966.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994533
  • [Keywords] NOTNLM ; pericardial mesothelioma / radiation
  •  go-up   go-down


7. Balli A, Lachat M, Gerber B, Baumgartner C, Glaus T: [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments]. Schweiz Arch Tierheilkd; 2003 Feb;145(2):82-7
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
  • Pericardial effusion recurred soon after pericardiocenteses, prescription of colchizine and again after balloon pericardiotomy.
  • After partial pericardectomy by thoracoscopy and after obtaining a histological diagnosis of mesothelioma adjuvant intracavitary chemotherapy using cisplatin was performed.
  • Already one week later the dog developed marked dyspnea due to severe pleural effusion.
  • Despite extensive treatments life span from initial presentation to euthanasia was only 5 months.
  • Necropsy revealed extensive mesothelioma metastases covering the whole pleura, epicardium and remaining pericardium.
  • Diagnostic and therapeutic aspects of (recurrent) pericardial effusion are discussed based on this case.
  • [MeSH-major] Cardiac Tamponade / veterinary. Dog Diseases / diagnosis. Heart Neoplasms / veterinary. Mesothelioma / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Euthanasia, Animal. Fatal Outcome. Male. Pericardial Effusion / etiology. Pericardial Effusion / therapy. Pericardial Effusion / veterinary. Pericardiectomy / veterinary. Pericardiocentesis / veterinary. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / therapy. Pleural Effusion, Malignant / veterinary. Recurrence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649954.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Vigneswaran WT, Stefanacci PR: Pericardial mesothelioma. Curr Treat Options Oncol; 2000 Oct;1(4):299-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial mesothelioma.
  • Primary pericardial mesothelioma is a rare but lethal disease.
  • Surgical resection remains the main treatment modality.
  • Most often the tumor invades the myocardium or the great vessels and therefore is at best palliative in relieving pericardial tamponade or constriction.
  • Addition of chemotherapy or radiation has been disappointing.
  • Newer therapeutic approaches for malignant pleural mesothelioma are likely to influence the treatment of pericardial mesothelioma in the future.
  • [MeSH-major] Heart Neoplasms / therapy. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Pericardium / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Jul;222(1):78-86 [7618973.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1210-2 [3474368.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):214-20 [7641017.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Am Rev Respir Dis. 1978 Aug;118(2):419-24 [697191.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):660-1 [7993848.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Environ Res. 1980 Dec;23(2):270-81 [7472312.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1982 Apr;81(4):520-3 [7067523.001]
  • [Cites] Postgrad Med J. 1992 Feb;68(796):137-9 [1570257.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Cancer. 1970 Oct;26(4):914-9 [5506612.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1987;21(3):273-5 [3438724.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):420-6 [1934246.001]
  • (PMID = 12057155.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


9. Santos C, Montesinos J, Castañer E, Sole JM, Baga R: Primary pericardial mesothelioma. Lung Cancer; 2008 May;60(2):291-3
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial mesothelioma.
  • Primary pericardial mesothelioma is a rare clinical entity; about 150 cases have been described in literature.
  • We present a 44-year-old man with a primary pericardial mesothelioma who received treatment under clinical essay with carboplatinum and pemetrexed reaching tumoral response; consolidation radiotherapy was administered.
  • Ten months after end of radiotherapy, tumoral progression was detected, and patient received second line of chemotherapy.
  • New cytotoxic drugs can improve the prognosis of this rare entity.
  • [MeSH-major] Heart Neoplasms / pathology. Heart Neoplasms / therapy. Mesothelioma / pathology. Mesothelioma / therapy. Pericardium / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Fatal Outcome. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Pemetrexed. Radiotherapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936406.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Eren NT, Akar AR: Primary pericardial mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):369-73
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial mesothelioma.
  • Pericardial mesothelioma is a rare cancer for which treatment options are limited.
  • Operative intervention in pericardial mesothelioma is primarily for effusion control, for cytoreduction before multimodal therapy, or to deliver and monitor innovative intrapericardial therapies.
  • Early detection of the disease is the only hope for survival.
  • Echocardiography, pathologic examination of pericardial fluid and pericardial biopsy, Gallium-67 scintigraph, Ber-EP4 antibody, and immunohistochemical procedures can be used.
  • Failure of surgical techniques is usually associated with mesothelioma with entrapped heart, a large solid tumor mass, and a long history of pericardial effusion.
  • No single treatment modality is efficient by itself.
  • The exact role of intracavitary chemotherapy or irradiation remains to be defined.
  • Preliminary clinical application of photodynamic therapy and attempts at inhibiting the effects of growth factors, such as vascular endothelial growth factor and platelet-derived growth factor, and vaccine treatments are being explored.
  • Adenoviral molecular chemotherapy recently completed phase I testing.
  • Clinical trials for pleural mesothelioma remain important as clinicians seek to improve the outcome for patients with pericardial mesothelioma.
  • In the future, combined therapeutic strategies involving radical surgery, radiotherapy, adjuvant chemotherapy, and immunomodulation may have a role in the treatment of pericardial mesotheliomas.
  • [MeSH-major] Heart Neoplasms / drug therapy. Heart Neoplasms / prevention & control. Heart Neoplasms / surgery. Mesothelioma / drug therapy. Mesothelioma / prevention & control. Mesothelioma / surgery. Pericardium / pathology
  • [MeSH-minor] Humans. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2001 Jun;42(3):425-7 [11398045.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):321-36 [9205997.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):695-700 [6668488.001]
  • [Cites] Ann Thorac Surg. 1967 Feb;3(2):162-5 [4951728.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Apr;114(4):817-21 [5026246.001]
  • [Cites] Pathol Int. 1999 Jul;49(7):658-62 [10504529.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Jpn Circ J. 2000 May;64(5):385-8 [10834456.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):167-72 [10395286.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Arch Pathol Lab Med. 1995 Mar;119(3):266-7 [7887781.001]
  • [Cites] Chest. 1980 Apr;77(4):559-61 [7357984.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):455S-460S [10619507.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2896-900 [11973650.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):875-7 [10810369.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1926-7 [10892948.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):81-5 [11243902.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1616-22 [9603146.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Sep;112(3):637-43 [8800150.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):77-81 [11836672.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):121-9 [11936818.001]
  • [Cites] Chirurg. 2000 Aug;71(8):877-86 [11013806.001]
  • (PMID = 12194802.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


11. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


12. Maruyama R, Sakai M, Nakamura T, Suemitsu R, Okamoto T, Wataya H, Nishiyama K, Kamei T, Ichinose Y: Triplet chemotherapy for malignant pericardial mesothelioma: a case report. Jpn J Clin Oncol; 2006 Apr;36(4):245-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
  • Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease.
  • A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone.
  • The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion.
  • The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drainage. Drug Administration Schedule. Female. Humans. Middle Aged. Neutropenia / chemically induced. Pericardial Effusion / pathology. Remission Induction. Survivors. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533802.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


13. Peregud-Pogorzelska M, Kaźmierczak J, Wojtarowicz A: Intracavitary mass as the initial manifestation of primary pericardial mesothelioma: a case report. Angiology; 2007 Apr-May;58(2):255-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracavitary mass as the initial manifestation of primary pericardial mesothelioma: a case report.
  • Computed tomography showed disseminated circular shadows sized up to 7 mm--most likely metastatic lesions--in both lungs.
  • The diagnosis of low-grade mesothelioma bifasicum was confirmed with histopathologic and immunohistochemical studies of the samples taken by thoracoscopy from parietal pleura, lung tumor, and diaphragm region.
  • Chemotherapy, which included gemcitabine and carboplatin, resulted in transient improvement of the clinical status of the patient and reduction of the tumor mass lasting several months followed by progression of the disease.
  • [MeSH-major] Heart Neoplasms / radiography. Heart Neoplasms / ultrasonography. Mesothelioma / radiography. Mesothelioma / ultrasonography. Pericardium
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diagnosis, Differential. Echocardiography. Fatal Outcome. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495278.001).
  • [ISSN] 0003-3197
  • [Journal-full-title] Angiology
  • [ISO-abbreviation] Angiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Saraiya B, Karantza-Wadsworth V, Stein MN, Chugh R, Mehnert J, Moss R, Lin Y, Poplin E: Phase I study of gemcitabine, docetaxel, and imatinib in refractory and relapsed solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13538 Background: The combination of the tyrosine kinase inhibitor imatinib with cytotoxic chemotherapy targets multiple pathways of tumor progression.
  • Five patients had lung cancer; 5, sarcoma; 3 ampullary-biliary tumors; 2 mesothelioma and bladder, 3, other.
  • The dose limiting toxicities were neutropenic fever, pleural and pericardial effusion after cycle 1 of chemotherapy.
  • The best response achieved was stable disease at 6 cycles in one patient each with mesothelioma and non small cell lung cancer (NSCLC) at the MTD.
  • Our results suggest possible drug-drug interactions that amplify toxicities with little initial evidence of improved tumor control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Molina Garrido MJ, Mora Rufete A, Rodríguez-Lescure A, Cascón Pérez JD, Ardoy F, Guillén Ponce C, Carrato Mena A: Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma. Clin Transl Oncol; 2006 Sep;8(9):694-6
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma.
  • The case of a 61-year-old woman who presented a recurrent symptomatic pericardial effusion and a malignant cardiac tamponade six months prior to the detection of a mediastinal anterior mass is described.
  • Diffuse malignant pericardial mesothelioma was diagnosed after mediastinal mass biopsy.
  • The patient underwent further oncological evaluation followed by chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis. Pericardial Effusion / etiology. Pericardium

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Clin. 1973;5(1):207-38 [4589961.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):208-12 [7838044.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Am J Cardiol. 1979 Nov;44(6):1110-4 [495505.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):622-5 [7496510.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • (PMID = 17005474.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Khalil LY, Szturmowicz M, Wawrzyńska L, Fijałkowska A, Kupis W, Maszkowska-Kopij K, Szczepulska E, Burakowska B, Tomkowski W, Torbicki A: [Diagnostic difficulties in primary mesothelioma]. Pneumonol Alergol Pol; 2004;72(5-6):221-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties in primary mesothelioma].
  • A 54-year-old woman with a history of fatigue and shortness of breath was found to have a pericardial effusion and mild mediastinal lymphadenopathy.
  • As lung cancer is one of the most frequent causes of pericardial metastases the patient was treated with cisplatin and vinblastin.
  • Following 5 courses of chemotherapy--given over a 4 month period--the amount of pericardial effusion and pericardial thickness did not change.
  • The material from pericardial biopsy was reexamined and positive immunostaining for calretinine was found.
  • The final diagnosis was primary pericardial mesothelioma of epithelioid type.
  • The case illustrates the difficulties in establishing diagnosis of primary pericardial mesothelioma which is a rare tumor with poor prognosis.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis. Pericardial Effusion / etiology. Pericardium
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757264.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Anão AO, Gil V, Trabulo M, Ribeiras R, Ferreira MM, Nogueira M, Seabra-Gomes R: [Primary mesothelioma of the pericardium: a clinical case]. Rev Port Cardiol; 2001 Nov;20(11):1125-30
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mesothelioma of the pericardium: a clinical case].
  • Medical therapy was initiated with no clinical benefit.
  • A diagnosis of primary pericardial mesothelioma was made after histological evaluation.
  • The prognosis for pericardial mesothelioma is poor due to its late diagnosis, the difficulty of surgical excision and poor response to radio- or chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826704.001).
  • [ISSN] 0870-2551
  • [Journal-full-title] Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • [ISO-abbreviation] Rev Port Cardiol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


18. Small GR, Nicolson M, Buchan K, Broadhurst P: Pericardial malignant mesothelioma: a latent complication of radiotherapy? Eur J Cardiothorac Surg; 2008 Apr;33(4):745-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial malignant mesothelioma: a latent complication of radiotherapy?
  • Pericardial diseases can be difficult to differentiate from myocardial conditions.
  • Post-embolectomy she developed cardiac failure.
  • Three months previously an acellular, sterile pericardial effusion had been drained.
  • Adjuvant chemotherapy and radiotherapy were administered.
  • Histology revealed pericardial epithelioid malignant mesothelioma.
  • Chemotherapy with pemetrexed and carboplatin was given.
  • Radiotherapy and asbestos exposure are both associated with pericardial mesothelioma and the aetiology in this case was not clear.
  • The condition carries a poor prognosis and is invariable fatal although newer chemotherapeutic regimens have prolonged survival times.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Heart Neoplasms / etiology. Mesothelioma / etiology. Neoplasms, Radiation-Induced / etiology. Pericardium

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280176.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Kindler HL, Herndon JE, Zhang C, Green MR, Cancer and Leukemia Group B: Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer; 2005 Jun;48(3):423-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
  • PURPOSE: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733).
  • Eligibility included a performance status of 0-2 by CALGB criteria, and no prior chemotherapy.
  • Twenty-five patients had pleural mesothelioma; two patients had peritoneal mesothelioma, and one patient had pericardial mesothelioma.
  • Three patients died of treatment-related toxicities.
  • CONCLUSION: Single-agent irinotecan in this dose and schedule has considerable toxicity in patients with malignant mesothelioma and has no anti-tumor activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893012.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome


21. Khalil MY, Mapa M, Shin HJ, Shin DM: Advances in the management of malignant mesothelioma. Curr Oncol Rep; 2003 Jul;5(4):334-41
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of malignant mesothelioma.
  • Malignant mesotheliomas are very aggressive tumors that originate from mesothelial cells, which form the serosal lining of the pleura, pericardial, and peritoneal cavities.
  • Finding effective chemotherapeutic treatment for malignant mesothelioma is a challenge.
  • There is no standard treatment because this tumor is relatively resistant to therapy.
  • A resurgence of interest has been expressed in novel therapies and conventional treatments used in different ways.
  • Several treatment modalities have been studied, including chemotherapy, radiotherapy, surgery, and immunotherapy.
  • Chemotherapy can be administered systemically or directly into the pleura.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Mesothelioma / pathology. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Genetic Therapy / methods. Humans. Immunotherapy / methods. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Neoplasm Staging. Pleural Neoplasms / mortality. Pleural Neoplasms / pathology. Pleural Neoplasms / therapy. Prognosis. Radiotherapy / methods. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Thoracic Surgical Procedures / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):1017-24 [12082024.001]
  • [Cites] Hum Gene Ther. 1998 May 1;9(7):1083-92 [9607419.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):511-5 [7630635.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):169-75 [9923859.001]
  • [Cites] Int J Oncol. 2001 May;18(5):1093-8 [11295061.001]
  • [Cites] Am J Clin Pathol. 1998 Sep;110(3):397-404 [9728617.001]
  • [Cites] Hum Gene Ther. 1999 Feb 10;10(3):463-75 [10048398.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):62-9 [11836670.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1436-42 [8021735.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2293-300 [10829050.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):167-72 [10395286.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 15;84(2):116-9 [8536224.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1985-91 [10570422.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(12):1514-21 [10930799.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):99-106 [9892193.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Chest. 1998 Jan;113(1 Suppl):66S-73S [9438693.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8 [9475525.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):361-6 [9352953.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1156-63 [8201377.001]
  • [Cites] Biochem Pharmacol. 2001 Jul 1;62(1):13-9 [11377392.001]
  • [Cites] Mol Carcinog. 1999 Oct;26(2):93-9 [10506753.001]
  • [Cites] Ann Thorac Surg. 1997 Feb;63(2):334-8 [9033296.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 20;87(24):1870-5 [7494231.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Jul 15;33(2):251-74 [3164248.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):313-9 [1988578.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):189-93 [11804869.001]
  • [Cites] Clin Lung Cancer. 1999 Aug;1(1):73-5 [14725755.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3009-16 [10506594.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):143-7 [11319288.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3533-44 [12177114.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Oct;29(2):173-9 [10959097.001]
  • [Cites] Lung Cancer. 2006 May;52(2):199-206 [16542747.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):233-9 [12925985.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):121-9 [11936818.001]
  • [Cites] Am Rev Respir Dis. 1991 Feb;143(2):408-22 [1990961.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Jul 1;47(1):1-28 [2357680.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] J Pathol. 2002 Jun;197(2):218-23 [12015746.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):956-60 [1616870.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Apr;117(4):759-65 [10096972.001]
  • (PMID = 12781077.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


22. Hasegawa S, Tanaka F: Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):317-23
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: current status and perspective in Japan and the world.
  • Malignant pleural mesothelioma (MPM) is associated with a poor prognosis; and to make things worse, its incidence is increasing throughout the world.
  • There are two types of surgical resection for MPM.
  • Pleurectomy/decortication (P/D) involves removal of as much of the visceral, parietal, and pericardial pleura and the tumor as possible without removing the underlying lung.
  • EPP comprises en bloc resection of visceral, parietal, and pericardial pleura and adjacent components such as ipsilateral lung, pericardium, and diaphragm, without opening the pleural cavity.
  • EPP was considered a highly dangerous procedure with a surgical mortality of more than 30% decades ago, but its current operative mortality/morbidity rates are 4%-9% and 60%, respectively.
  • In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Thoracic Surgical Procedures
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Japan. Laparoscopy. Mediastinoscopy. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Thoracoscopy. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 1999 Dec;16(6):619-23 [10647830.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2629-30 [12860935.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):981-7 [16678579.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 May;31(5):765-70; discussion 770-1 [17337201.001]
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):1988-92; discussion 1992-3 [16305830.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Radiology. 2006 Nov;241(2):589-94 [17005770.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):102-6 [18048410.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):175-6 [17409850.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):907-12 [9528833.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1172-8 [8501504.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):489-94 [8876892.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S25-6 [15950795.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Sep;130(3):905-6 [16153957.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S71-4 [15950805.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):146-53 [16770231.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Am J Ind Med. 2006 Jan;49(1):1-7 [16362942.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1249-53 [17066226.001]
  • [Cites] Ann Thorac Surg. 2006 Dec;82(6):2337; author reply 2337-8 [17126172.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):57-65 [11162867.001]
  • [Cites] Kyobu Geka. 2007 Jan;60(1):19-24 [17249533.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1449-58 [17704250.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):957-65 [17909360.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):279-87 [11679187.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1414-8 [17532931.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Feb;11(2):210-3 [9080144.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S24-9 [17686442.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 18607677.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 60
  •  go-up   go-down


23. Maggi G, Casadio C, Cianci R, Rena O, Ruffini E: Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2001 Mar;19(3):346-50
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality management of malignant pleural mesothelioma.
  • OBJECTIVE: We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM).
  • METHODS: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy.
  • Surgery consisted of pleurectomy/decortication (P/D) or pleural-pericardial-pneumonectomy and diaphragm (PPPD).
  • Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded.
  • (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Paclitaxel / administration & dosage. Pneumonectomy / methods. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251277.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Bonnette P: [Radical surgery for mesothelioma]. Cancer Radiother; 2007 Jan-Feb;11(1-2):101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radical surgery for mesothelioma].
  • Good results obtained by the team from Boston increased the interest in pleuropneumonectomy for mesothelioma.
  • The high rate of peritoneal (26-31%), controlateral pleural and pericardial recurrences justify the routine practice of preoperative laparoscopy and controlateral thoracoscopy and a pleuropneumonectomy without pericardotomy and diaphragmatic resection.
  • Chemotherapy may be performed postoperatively.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Laparoscopy. Neoplasm Recurrence, Local / pathology. Pleura / surgery. Pneumonectomy. Radiotherapy, Adjuvant. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949849.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


25. Crispi S, Cardillo I, Spugnini EP, Citro G, Menegozzo S, Baldi A: Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets. Curr Cancer Drug Targets; 2010 Feb;10(1):19-26
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
  • Malignant mesothelioma (MM) is a rare, highly aggressive tumor that arises from the surface serosal cells (pleural, peritoneal and pericardial cavities).
  • The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future.
  • Goal of this article is to summarize the most recent advances in molecular pathogenesis of mesothelioma with particular emphasis on genes that could be considered as biomarkers or therapeutic targets and discuss possible clinical implications of these findings.
  • [MeSH-major] Biomarkers, Tumor / genetics. Mesothelioma. Peritoneal Neoplasms. Pleural Neoplasms
  • [MeSH-minor] Animals. Asbestos / toxicity. Carcinogens / toxicity. Gene Expression Regulation, Neoplastic. Humans. Lung Neoplasms / chemically induced. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Mice. Mutation

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088796.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinogens; 1332-21-4 / Asbestos
  • [Number-of-references] 105
  •  go-up   go-down


26. Maisch B, Ristić AD, Pankuweit S, Neubauer A, Moll R: Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J; 2002 Oct;23(20):1625-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin.
  • AIMS: To evaluate the clinical efficacy, safety, and long-term effect of intrapericardial treatment with cisplatin in large neoplastic pericardial effusions.
  • METHODS AND RESULTS: Out of the registry of 260 patients undergoing pericardiocentesis, 42 patients with neoplastic pericardial effusion (69% males, mean age 58.8+/-13.2 years) were selected for treatment with cisplatin (single instillation of 30 mg.m(-2) x 24h(-1)) in addition to the tumour-specific systemic chemotherapy.
  • Pericardial effusion and biopsy analyses included biochemistry, cytology, serology, microbiology, histology, immunohistology, and PCR.
  • The following malignancies were established: lung cancer, 52.4%; breast cancer, 19.0%; Hodgkin's disease, 4.8%; oesophageal cancer, 2.4%; mesothelioma, 2.4%; colon cancer, 4.8%; and undifferentiated cancer of unknown origin, 14.2%.
  • Cisplatin appeared to prevent recurrence of pericardial effusion during the first 3 months of the follow-up in 92.8%, and after 6 months in 83.3% of the patients.
  • CONCLUSION: Intrapericardial treatment with cisplatin appeared to successfully prevent recurrences of neoplastic pericardial effusion.
  • The treatment was more successful in lung than in breast cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Neoplasms / complications. Pericardial Effusion / drug therapy. Pericardial Effusion / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12323163.001).
  • [ISSN] 0195-668X
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Mandić A, Djurdjević S, Popov M, Krnojelać D, Kukić B: Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report. J BUON; 2004 Jan-Mar;9(1):91-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.
  • Malignant schwannoma and peritoneal malignant mesothelioma (MM) are very rare tumors.
  • MM arises primarily from the surface serosal cells of the pleural, peritoneal, and pericardial cavities.
  • The patient was operated on for second time and MM was diagnosed as second primary tumor, along with recurrence of the malignant schwannoma.
  • The patient received postoperative adjuvant external beam radiotherapy and chemotherapy.
  • Despite combined-modality treatment the disease progressed and the patient was operated on for third time 2.5 years after the first operation with partial tumor resection.
  • Early diagnosis of these two types of tumors is very difficult because of unspecific clinical symptoms.
  • Singlemodality therapy of these tumors has shown poor results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385835.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


28. Vander Salm TJ: Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg; 2000 Apr;12(2):89-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The benign tumors include rhabdomyomas, fibromas, papillary fibroelastomas, hemangiomas, pericardial cysts, lipomas, hamartomas, teratomas, mesotheliomas, and paragangliomas or pheochromocytomas.
  • Local invasion can lead to arrhythmias or pericardial effusions with tamponade.
  • The echocardiographic appearance may also allow quite accurate prediction of the tumor type and whether it is malignant or benign.
  • Magnetic resonance imaging serves as the next most important test where the density of T1 and T2 images may allow tumor cell type identification.
  • For patients with unresectable sarcomas, radiation and chemotherapy may be used, but without great expectation of successful results.
  • [MeSH-minor] Fibroma / diagnosis. Fibroma / surgery. Hamartoma / diagnosis. Hamartoma / surgery. Heart Septum / pathology. Heart Transplantation. Hemangioma / diagnosis. Hemangioma / surgery. Humans. Hypertrophy. Mesothelioma / diagnosis. Mesothelioma / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Prognosis. Rhabdomyoma / diagnosis. Rhabdomyoma / surgery. Teratoma / diagnosis. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807431.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 69
  •  go-up   go-down


29. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • The best treatment of this disease is radical surgical resection.
  • No definitive data exist about the role of chemotherapy.
  • A right pleuropneumonectomy and pericardial resection was performed through a right hemiclam-shell approach.
  • In consideration of the apparent local radicality we did not perform any adjuvant treatment.
  • Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • When there is suspicion of a malignant form neoadjuvant chemotherapy can represent a further tool to control poorly differentiated and large tumors, and a wide surgical resection of the lesion must be performed.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


30. Davidson B: Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog; 2007 Dec;13(3):189-227
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of cancer cells in effusions within the serosal (peritoneal, pleural, and pericardial) cavities is a clinical manifestation of advanced-stage cancer and is associated with poor survival.
  • Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site.
  • Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure.
  • In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases.
  • In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression.
  • The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298385.001).
  • [ISSN] 0893-9675
  • [Journal-full-title] Critical reviews in oncogenesis
  • [ISO-abbreviation] Crit Rev Oncog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / EFN-4 protein, C elegans; 0 / Ephrins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, Growth Factor
  • [Number-of-references] 167
  •  go-up   go-down


31. Sonoda S, Kumagawa Y, Inada E: A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma. J Anesth; 2010 Dec;24(6):926-9
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He subsequently underwent right extrapleural pneumonectomy because a right pleural metastatic lesion had developed.
  • Emergent re-thoracotomy was performed and the heart was found to be malrotated and herniated from an upper defect of the pericardial patch in the right thoracic cavity.
  • The heart was returned to the pericardium and the defect was covered with a pericardial patch.
  • The incidence of cardiac herniation after extrapleural pneumonectomy following chemotherapy for malignant pleural mesothelioma has been reported to be around 3%.
  • [MeSH-minor] Adult. Anesthesia, General. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Electrocardiography. Humans. Male. Monitoring, Intraoperative. Respiration, Artificial. Supine Position. Thoracotomy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hernia.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2007 Sep;73(9):906-8 [17939424.001]
  • [Cites] J Thorac Cardiovasc Surg. 1970 Mar;59(3):443-6 [5415089.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] J Thorac Cardiovasc Surg. 1979 Oct;78(4):623-5 [480972.001]
  • [Cites] Anaesth Intensive Care. 2005 Jun;33(3):403-9 [15973927.001]
  • [Cites] Chest. 2000 Apr;117(4):1184-5 [10767257.001]
  • [Cites] Thorax. 1974 Sep;29(5):545-52 [4428454.001]
  • [Cites] Anesth Analg. 1986 Oct;65(10):1085-8 [3752560.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Jan;19(1):89-91 [11163569.001]
  • [Cites] J Thorac Imaging. 2007 Aug;22(3):280-2 [17721344.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Acta Anaesthesiol Scand. 1992 Nov;36(8):842-5 [1466225.001]
  • [Cites] Ann Surg. 1948 Nov;128(5):1012-4 [17859240.001]
  • [Cites] Anesthesiology. 1984 Apr;60(4):362-4 [6703392.001]
  • (PMID = 20737279.001).
  • [ISSN] 1438-8359
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cardiotonic Agents; VTD58H1Z2X / Dopamine
  •  go-up   go-down






Advertisement